Laboratory of Nutrition and Metabolic Surgery (LIM-35), Department of Gastroenterology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Human Development & Health, Faculty of Medicine, University of Southampton, Southampton, UK.
JPEN J Parenter Enteral Nutr. 2020 Sep;44(7):1169-1170. doi: 10.1002/jpen.1933. Epub 2020 Jun 24.
In this letter we discuss the proposition of Bristian BR (2020) to use the intravenous administration of fish-oil emulsions in critically ill patients with Coronavirus Disease 2019 (COVID-19). We consider that immune-modulatory properties of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, rapidly provided in high amounts by fish-oil emulsions, may be important to change the course of COVID-19's death pathway. Prescriptions should be based on body weight (eg, 0.2-g pure fish-oil lipid emulsion/kg body weight/d) and also should consider combining the parenteral administration of fish-oil emulsions with low oral aspirin intake to trigger resolvin synthesis from EPA and DHA.
在这封信中，我们讨论了 BR 提出的在 2019 年冠状病毒病（COVID-19）危重症患者中静脉给予鱼油乳剂的建议。我们认为，鱼油乳剂快速提供大量的二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）的免疫调节特性可能对改变 COVID-19 的死亡途径很重要。处方应基于体重（例如，0.2 克纯鱼油脂质乳剂/千克体重/天），还应考虑将鱼油乳剂的静脉给药与低剂量口服阿司匹林联合使用，以从 EPA 和 DHA 触发 resolvin 的合成。
